News headlines about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Corcept Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.9462880147535 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s analysis:
- Weakness In Corcept Shares Is ‘Overdone,’ According To Analyst (finance.yahoo.com)
- Can Corcept Therapeutics Incorporated’s (CORT) ROE Continue To Surpass The Industry Average? (finance.yahoo.com)
- Mid-Morning Market Update: Markets Open Higher; Wal-Mart Reports $20B Buyback Plan (feeds.benzinga.com)
- ETFs with exposure to Corcept Therapeutics, Inc. : October 9, 2017 (finance.yahoo.com)
- Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 (finance.yahoo.com)
Shares of Corcept Therapeutics (CORT) opened at 18.69 on Wednesday. Corcept Therapeutics has a 12-month low of $6.11 and a 12-month high of $20.77. The company has a market capitalization of $2.12 billion, a P/E ratio of 92.99 and a beta of 2.12. The company has a 50 day moving average of $17.66 and a 200-day moving average of $13.17.
Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.02. The company had revenue of $35.56 million for the quarter, compared to analyst estimates of $31.37 million. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. The company’s revenue for the quarter was up 80.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.01 EPS. On average, equities analysts anticipate that Corcept Therapeutics will post $0.42 EPS for the current fiscal year.
A number of analysts recently commented on the stock. Zacks Investment Research downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. BidaskClub upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, August 18th. Piper Jaffray Companies boosted their target price on shares of Corcept Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, September 8th. Finally, Ladenburg Thalmann Financial Services set a $20.00 target price on shares of Corcept Therapeutics and gave the stock a “buy” rating in a report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $16.17.
In other news, Director David L. Mahoney sold 23,006 shares of the firm’s stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $12.50, for a total value of $287,575.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David L. Mahoney sold 6,091 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $12.50, for a total transaction of $76,137.50. The disclosure for this sale can be found here. Insiders sold a total of 36,091 shares of company stock worth $451,138 in the last ninety days. Insiders own 19.20% of the company’s stock.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.